

Governing Body Meeting			
Date:	Tuesday 13 July 2021	Time:	2:30 pm
Venue:	MS Teams		
Questions from the general public received in advance			

Email received 27/05/2021

NICE published new guidance on Atrial Fibrillation NG196 on 27 April 2021 which includes the following recommendation:

“For people already established and stable on a vitamin K antagonist, the committee agreed that the benefits of changing to a direct-acting anticoagulant need to be discussed. Therefore, the risks and benefits of changing medication, the person's time in therapeutic range and the person's preferences should be explored at their next routine appointment.”

- A. Does the CCG have a general process to ensure that applicable NICE guidance is implemented?
- B. Can you give an assurance that the above recommendation will be carried out?

Liverpool CCG Response:

- A. Liverpool CCG has a Clinical Effectiveness Committee, which provides assurance to the Governing Body that the CCG is developing and implementing clinical policies in line with the organisation's strategic direction and in accordance with national clinical guidance and local priorities.

Individual service providers are also responsible for ensuring they are responding to relevant clinical guidance.

- B. A full review and consideration of the most appropriate medication for a patient form part of a routine anti-coagulant clinic appointment and the risks and benefits would be considered and discussed with a patient when attending for their review. Where a vitamin K antagonist is not appropriate, the service would support GPs to manage the change in a patient's treatment to a DOAC.